AR134366A1 - Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina - Google Patents

Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina

Info

Publication number
AR134366A1
AR134366A1 ARP240103147A ARP240103147A AR134366A1 AR 134366 A1 AR134366 A1 AR 134366A1 AR P240103147 A ARP240103147 A AR P240103147A AR P240103147 A ARP240103147 A AR P240103147A AR 134366 A1 AR134366 A1 AR 134366A1
Authority
AR
Argentina
Prior art keywords
methods
antibody
compositions
treating
preventing
Prior art date
Application number
ARP240103147A
Other languages
English (en)
Inventor
Aubin Michalon
Michael Salzmann
Rahul Godawat
Siguang Sui
Original Assignee
Neurimmune Ag
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Ag, Alexion Pharma Inc filed Critical Neurimmune Ag
Publication of AR134366A1 publication Critical patent/AR134366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos antitranstiretina (TTR), polinucleótidos correspondientes y vectores de expresión, así como composiciones (por ejemplo, composiciones farmacéuticas) y artículos de elaboración relacionados que contienen el anticuerpo anti-TTR como un fármaco. También métodos para tratar o prevenir la amiloidosis mediada por transtiretina (ATTR) en un sujeto que lo necesite con el uso de las composiciones farmacéuticas. Además, métodos para validar, identificar y cribar un fármaco que disminuye los amiloides con el uso de formación de imágenes de células vivas de alta resolución, así como métodos para producir una composición farmacéutica de un fármaco que disminuye los amiloides y kits adecuados para su uso en dichos métodos.
ARP240103147A 2023-11-15 2024-11-15 Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina AR134366A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2023081969 2023-11-15
EP2024064293 2024-05-23
EP2024077454 2024-09-30

Publications (1)

Publication Number Publication Date
AR134366A1 true AR134366A1 (es) 2026-01-07

Family

ID=93562471

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240103147A AR134366A1 (es) 2023-11-15 2024-11-15 Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina

Country Status (3)

Country Link
AR (1) AR134366A1 (es)
TW (1) TW202528347A (es)
WO (1) WO2025104243A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ES2242997T3 (es) 1997-03-14 2005-11-16 Biogen Idec Inc. Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo.
EP1340088B1 (en) 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP2906599B1 (en) 2012-10-12 2019-07-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
US10344080B2 (en) 2013-12-20 2019-07-09 Neurimmune Holding Ag Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
CU20200042A7 (es) * 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
US20210400932A1 (en) 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
KR20220012231A (ko) * 2019-04-24 2022-02-03 리젠엑스바이오 인크. 완전-인간 번역 후 변형된 항체 치료제
CN115551886A (zh) 2020-05-12 2022-12-30 生物控股有限公司 用于ttr淀粉样变性的联合疗法
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
AU2023380952A1 (en) 2022-11-15 2025-06-26 Neurimmune Ag Pharmaceutical compositions for treating or preventing transthyretin-mediated amyloidosis

Also Published As

Publication number Publication date
WO2025104243A1 (en) 2025-05-22
TW202528347A (zh) 2025-07-16

Similar Documents

Publication Publication Date Title
McLure et al. A comparative HST imaging study of the host galaxies of radio-quiet quasars, radio-loud quasars and radio galaxies—I
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CL2021000293A1 (es) Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575)
CL2010000792A1 (es) Anticuerpo monoclonal que se une a integrina alfavbeta6 o fragmento que enlaza a antigeno que comprende los mismos cdr que un anticuerpo producido por el hibridoma 7.1c5 (numero de acceso atcc pta-3900); composicion farmaceutica que lo comprende; hibridoma; y su uso (div.sol.no.513-03).
CL2024002658A1 (es) Moléculas de unión contra fralfa
Adunlin et al. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis
MX2022008214A (es) Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
MX2021013657A (es) Conjugados de anticuerpo y farmaco.
ECSP23042551A (es) Conjugados de anticuerpo y fármaco
CO2022018547A2 (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CL2025001171A1 (es) Compuestos que median la degradacion de proteinas y metodos de uso de los mismos
AR128060A1 (es) Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos
ECSP22055004A (es) Anticuerpos anti?mertk y m?todos de uso de los mismos
CL2023003605A1 (es) Conjugados de neodegradador-anticuerpo anti-cd33
Mitta et al. A new morphotype of lower jaw associated with Calliphylloceras (Cephalopoda: Ammonoidea) from the Middle Jurassic of the Northern Caucasus
AR134366A1 (es) Anticuerpo antitranstiretina, composiciones que comprenden dicho anticuerpo y métodos para tratar o prevenir la amiloidosis mediada por transtiretina
BR112022016351A2 (pt) Compostos heterocíclicos fundidos e seu uso como agentes de controle de pragas
Lake et al. Translations of the practice environment scale of the nursing work index: a systematic review
Haug et al. Simple 3D images from fossil and Recent micromaterial using light microscopy
BR112021025247A2 (pt) Compostos heterocíclicos fusionados e seu uso como agentes de controle de pragas
Mora‐Navarro et al. Synthetic antimicrobial β‐peptide in dual‐treatment with fluconazole or ketoconazole enhances the in vitro inhibition of planktonic and biofilm Candida albicans
CL2023002992A1 (es) Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco
Linauskienė et al. Solvent Orange 60 is a potent contact sensitizer in occupational and everyday life